Business Context and Reporting Period
This Form 8-K is a current report filed by Aquinox Pharmaceuticals, Inc. (not Neurogene Inc.) on February 13, 2015, covering events occurring on February 13 and February 16, 2015. The company is incorporated in Delaware and headquartered in Vancouver, B.C., Canada.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Board Retainer: $35,000
- Audit Committee Retainer: $7,500
- Meeting Fee: $500 per in-person regular board meeting
- Stock Option Grant: 8,333 shares of common stock with a three-year annual vesting schedule
Material Changes
The filing reports the following changes to the Board of Directors:
- Appointment: Sean P. Nolan was elected as a Class I director and appointed to the Audit Committee, effective February 16, 2015. His term lasts until the 2015 Annual Meeting of Stockholders.
- Resignation: Elaine Jones resigned from the Board on February 13, 2015. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Unusual Items
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No risks or contingencies were disclosed other than the standard indemnification agreement entered into with Mr. Nolan, which covers legal expenses, judgments, fines, and settlement amounts. There are no related person transactions or family relationships disclosed between Mr. Nolan and other directors or officers.
Investor Verification Checklist
- Verify the correct registrant name is Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Confirm the effective date of Sean P. Nolan's directorship and Audit Committee appointment (February 16, 2015).
- Review the vesting schedule for the 8,333 stock options granted to Mr. Nolan.
- Check the company's previous Form S-1 (No. 333-193615) for the full text of the standard indemnification agreement referenced in Exhibit 10.1.